Marshall Wace North America’s Aegerion Pharmaceuticals AEGR Stock Holding History

Marshall Wace North America’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	$1.27M	Buy	+17,858	New	+$1.37M	0.03%	360

Other funds holding AEGR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace North America's AEGR Position: Q4 2013 in Review

Marshall Wace North America opened a new position in Aegerion Pharmaceuticals (AEGR) in Q4 2013: 17,858 shares worth $1.27M. The stake represents 0.03% of the portfolio and ranks #360 among its holdings.

150 funds tracked by Wall St. Rank hold AEGR as of Q4 2013.

Marshall Wace North America held 17,858 shares of Aegerion Pharmaceuticals worth $1.27M as of Q4 2013.
Aegerion Pharmaceuticals was a new Marshall Wace North America position in Q4 2013.
Aegerion Pharmaceuticals made up 0.03% of Marshall Wace North America's portfolio in Q4 2013, its #360 holding.
150 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2013.

Based on Marshall Wace North America's 13F filing for Q4 2013, filed 14 Feb 2014.